CL2011002962A1 - Uso de al menos un ligando especifico de integrina para el tratamiento de cancer, y donde el medicamento es para ser usado en combinacion con al menos un agente adicional seleccionado de a) uno o mas agentes alquilantes y b) uno o mas agentes quimioterapeuticos diferente a los anteriores. - Google Patents
Uso de al menos un ligando especifico de integrina para el tratamiento de cancer, y donde el medicamento es para ser usado en combinacion con al menos un agente adicional seleccionado de a) uno o mas agentes alquilantes y b) uno o mas agentes quimioterapeuticos diferente a los anteriores.Info
- Publication number
- CL2011002962A1 CL2011002962A1 CL2011002962A CL2011002962A CL2011002962A1 CL 2011002962 A1 CL2011002962 A1 CL 2011002962A1 CL 2011002962 A CL2011002962 A CL 2011002962A CL 2011002962 A CL2011002962 A CL 2011002962A CL 2011002962 A1 CL2011002962 A1 CL 2011002962A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer
- drug
- treatment
- combination
- agent selected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Uso de al menos un ligando específico de integrina para el tratamiento de cáncer, y donde el medicamento es para ser usado en combinación con al menos un agente adicional seleccionado de A) Uno o más agentes alquilantes y B) Uno o más agentes quimioterapéuticos diferente a los anteriores.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09006941 | 2009-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011002962A1 true CL2011002962A1 (es) | 2012-06-01 |
Family
ID=43223150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011002962A CL2011002962A1 (es) | 2009-05-25 | 2011-11-24 | Uso de al menos un ligando especifico de integrina para el tratamiento de cancer, y donde el medicamento es para ser usado en combinacion con al menos un agente adicional seleccionado de a) uno o mas agentes alquilantes y b) uno o mas agentes quimioterapeuticos diferente a los anteriores. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20120130146A1 (es) |
EP (1) | EP2445534A2 (es) |
JP (1) | JP2012528079A (es) |
KR (1) | KR20120104491A (es) |
CN (1) | CN102448497A (es) |
AU (1) | AU2010252280A1 (es) |
BR (1) | BRPI1011206A2 (es) |
CA (1) | CA2763275A1 (es) |
CL (1) | CL2011002962A1 (es) |
EA (1) | EA201101651A1 (es) |
EC (1) | ECSP11011552A (es) |
IL (1) | IL216537A0 (es) |
MX (1) | MX2011012491A (es) |
NZ (1) | NZ597339A (es) |
SG (1) | SG176103A1 (es) |
WO (1) | WO2010136168A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2805338A1 (en) * | 2010-07-16 | 2012-01-19 | Merck Patent Gmbh | Peptide for use in the treatment of breast cancer and/or bone metastases |
US9693957B2 (en) | 2011-07-08 | 2017-07-04 | The University Of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
JP6426001B2 (ja) | 2011-11-17 | 2018-11-21 | グリア エスピー ゼット.オー.オー. | 神経膠腫を治療するための組成物および方法 |
KR101470700B1 (ko) * | 2011-11-25 | 2014-12-12 | 서울대학교산학협력단 | 표적 항암제의 내성 극복 방법 |
JP6458007B2 (ja) * | 2014-04-04 | 2019-01-23 | 大鵬薬品工業株式会社 | 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |
US10806694B2 (en) | 2014-10-14 | 2020-10-20 | The University Of Chicago | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
CN110731961A (zh) | 2014-10-14 | 2020-01-31 | 芝加哥大学 | 金属有机框架、药物制剂及其在制备药物中的用途 |
US11246877B2 (en) | 2016-05-20 | 2022-02-15 | The University Of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
WO2019002943A1 (en) * | 2017-06-29 | 2019-01-03 | Insightec, Ltd. | SIMULATION-BASED TREATMENT PLANNING BASED ON SIMULATION |
JP7364552B2 (ja) | 2017-08-02 | 2023-10-18 | ザ ユニバーシティ オブ シカゴ | X線誘起光線力学療法、放射線療法、放射線力学療法、化学療法、免疫療法、及びそれらの任意の組み合わせのための、ナノスケール金属有機層及び金属有機ナノプレート |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
US4792525A (en) | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4661111A (en) | 1982-08-04 | 1987-04-28 | La Jolla Cancer Research Foundation | Polypeptide |
US4589881A (en) | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4578079A (en) | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4517686A (en) | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US4614517A (en) | 1982-08-04 | 1986-09-30 | La Jolla Cancer Research Foundation | Tetrapeptide |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
WO1991003493A1 (en) | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
WO1992005793A1 (en) | 1990-10-05 | 1992-04-16 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
CA2097060A1 (en) | 1990-12-04 | 1992-06-05 | Peter J. Curtis | Bifunctional antibodies and method of preparing same |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US5407804A (en) | 1992-05-22 | 1995-04-18 | Applied Genetics Inc. | Assays for O6 -methylguanine-DNA methyltransferase |
GB9224888D0 (en) | 1992-11-27 | 1993-01-13 | Univ Singapore | Monoclonal antibody |
AU690528B2 (en) | 1992-12-04 | 1998-04-30 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
ES2186720T3 (es) | 1994-05-27 | 2003-05-16 | Merck & Co Inc | Composiciones para inhibir la reabsorcion osea mediada por osteoclastos. |
ZA955391B (en) | 1994-06-29 | 1996-02-09 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
JPH10504808A (ja) | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗物質 |
IT1271688B (it) | 1994-08-04 | 1997-06-04 | Menarini Ricerche Sud Spa | Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche |
WO1996006087A1 (en) | 1994-08-22 | 1996-02-29 | Smithkline Beecham Corporation | Bicyclic compounds |
WO1996026190A1 (en) | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Integrin receptor antagonists |
US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
SI0910563T1 (en) | 1995-06-29 | 2003-10-31 | Smithkline Beecham Corporation | Integrin receptor antagonists |
DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
CN1209744A (zh) | 1995-12-29 | 1999-03-03 | 史密丝克莱恩比彻姆公司 | 玻连蛋白受体拮抗剂 |
PL327919A1 (en) | 1995-12-29 | 1999-01-04 | Smithkline Beecham Corp | Antagonists of vitronectin receptors |
EP0906103A1 (en) | 1995-12-29 | 1999-04-07 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
AP806A (en) | 1996-03-20 | 2000-01-28 | Aventis Pharma Sa | Tricyclic compounds having activity specific for integrins, particularly avB3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same. |
CA2251017A1 (en) | 1996-04-10 | 1997-10-16 | Mark E. Duggan | .alpha.v.beta.3 antagonists |
US5925655A (en) | 1996-04-10 | 1999-07-20 | Merck & Co., Inc. | αv β3 antagonists |
WO1997041844A1 (en) | 1996-05-09 | 1997-11-13 | Alcon Laboratories, Inc. | Combinations of angiostatic compounds |
PL330241A1 (en) | 1996-05-31 | 1999-05-10 | Scripps Research Inst | Methods of and compositions useful in inhibiting angiogenesis |
US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
US5981546A (en) | 1996-08-29 | 1999-11-09 | Merck & Co., Inc. | Integrin antagonists |
EP0934305A4 (en) | 1996-08-29 | 2001-04-11 | Merck & Co Inc | INTEGRINE ANTAGONISTS |
EP0946180A4 (en) | 1996-10-07 | 2003-07-23 | Smithkline Beecham Corp | METHODS FOR STIMULATING BONE FORMATION |
JP2001504456A (ja) | 1996-10-30 | 2001-04-03 | メルク エンド カンパニー インコーポレーテッド | インテグリン拮抗薬 |
DE69720771T2 (de) | 1996-10-30 | 2004-01-29 | Merck & Co Inc | Integrin antagonist |
US5919792A (en) | 1996-10-30 | 1999-07-06 | Merck & Co., Inc. | Integrin antagonists |
DE69720062D1 (de) | 1996-12-09 | 2003-04-24 | Lilly Co Eli | Integrin antagonisten |
DE19653646A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
DE19653645A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
CO4920232A1 (es) | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
CA2277273C (en) | 1997-01-17 | 2008-03-25 | Merck & Co., Inc. | Integrin antagonists |
JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック,インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
CA2297910A1 (en) | 1997-07-25 | 1999-02-04 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
JP2001511452A (ja) | 1997-08-04 | 2001-08-14 | スミスクライン・ビーチャム・コーポレイション | インテグリン受容体アンタゴニスト |
WO1999011626A1 (en) | 1997-09-04 | 1999-03-11 | Smithkline Beecham Corporation | Integrin receptor antagonists |
DZ2609A1 (fr) | 1997-09-19 | 2003-03-01 | Smithkline Beecham Corp | Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant. |
FR2768734B1 (fr) | 1997-09-24 | 2000-01-28 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
CN1273529A (zh) | 1997-09-24 | 2000-11-15 | 史密丝克莱恩比彻姆公司 | 玻连蛋白受体拮抗剂 |
FR2768736B1 (fr) | 1997-09-24 | 2000-05-26 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
WO1999015178A1 (en) | 1997-09-24 | 1999-04-01 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
ES2243015T3 (es) | 1997-12-17 | 2005-11-16 | MERCK & CO., INC. | Antagonistas del receptor de integrina. |
CA2315370A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
PL341095A1 (en) | 1997-12-17 | 2001-03-26 | Merck & Co Inc | Compounds acting as antagonists of integrin receptor |
PL341215A1 (en) | 1997-12-17 | 2001-03-26 | Merck & Co Inc | Antagonists of integrin receptors |
US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
CA2319160A1 (en) | 1998-01-23 | 1999-07-29 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Monoclonal antibody anti .alpha.v-integrin and its use to inhibit .alpha.v.beta.6-integrin attachment to fibronectin |
JP2002521450A (ja) | 1998-07-29 | 2002-07-16 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体アンタゴニスト |
WO2000009503A1 (en) | 1998-08-13 | 2000-02-24 | Merck & Co., Inc. | Integrin receptor antagonists |
DE19842415A1 (de) | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
CA2356748A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia |
EP1187592B1 (en) | 1999-06-02 | 2007-08-01 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
US6773897B2 (en) | 2000-09-29 | 2004-08-10 | The Johns Hopkins University School Of Medicine | Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents |
CN101370522A (zh) * | 2006-01-18 | 2009-02-18 | 默克专利有限公司 | 使用整联蛋白配体治疗癌症的特别疗法 |
WO2008087025A2 (en) * | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Specific therapy and medicament using integrin ligands for treating cancer |
-
2010
- 2010-05-25 US US13/322,391 patent/US20120130146A1/en not_active Abandoned
- 2010-05-25 AU AU2010252280A patent/AU2010252280A1/en not_active Abandoned
- 2010-05-25 NZ NZ597339A patent/NZ597339A/xx not_active IP Right Cessation
- 2010-05-25 CA CA2763275A patent/CA2763275A1/en not_active Abandoned
- 2010-05-25 SG SG2011084381A patent/SG176103A1/en unknown
- 2010-05-25 WO PCT/EP2010/003162 patent/WO2010136168A2/en active Application Filing
- 2010-05-25 EA EA201101651A patent/EA201101651A1/xx unknown
- 2010-05-25 JP JP2012511202A patent/JP2012528079A/ja active Pending
- 2010-05-25 KR KR1020117030945A patent/KR20120104491A/ko not_active Application Discontinuation
- 2010-05-25 BR BRPI1011206A patent/BRPI1011206A2/pt not_active Application Discontinuation
- 2010-05-25 CN CN2010800227000A patent/CN102448497A/zh active Pending
- 2010-05-25 EP EP20100721342 patent/EP2445534A2/en not_active Withdrawn
- 2010-05-25 MX MX2011012491A patent/MX2011012491A/es not_active Application Discontinuation
-
2011
- 2011-11-22 IL IL216537A patent/IL216537A0/en unknown
- 2011-11-24 CL CL2011002962A patent/CL2011002962A1/es unknown
- 2011-12-23 EC EC2011011552A patent/ECSP11011552A/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL216537A0 (en) | 2012-02-29 |
SG176103A1 (en) | 2011-12-29 |
NZ597339A (en) | 2013-10-25 |
CA2763275A1 (en) | 2010-12-02 |
WO2010136168A2 (en) | 2010-12-02 |
EP2445534A2 (en) | 2012-05-02 |
BRPI1011206A2 (pt) | 2016-03-15 |
MX2011012491A (es) | 2011-12-14 |
AU2010252280A1 (en) | 2012-01-19 |
ECSP11011552A (es) | 2012-01-31 |
JP2012528079A (ja) | 2012-11-12 |
WO2010136168A8 (en) | 2011-09-22 |
US20120130146A1 (en) | 2012-05-24 |
EA201101651A1 (ru) | 2012-08-30 |
CN102448497A (zh) | 2012-05-09 |
KR20120104491A (ko) | 2012-09-21 |
WO2010136168A3 (en) | 2011-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011002962A1 (es) | Uso de al menos un ligando especifico de integrina para el tratamiento de cancer, y donde el medicamento es para ser usado en combinacion con al menos un agente adicional seleccionado de a) uno o mas agentes alquilantes y b) uno o mas agentes quimioterapeuticos diferente a los anteriores. | |
CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
UY29086A1 (es) | Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos. | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
CL2009000545A1 (es) | Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer. | |
CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
CL2011001811A1 (es) | Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico. | |
CO6341551A2 (es) | Agentes quimioterapeuticos de cannabinoides en combinacion con no cannabinoides (e.g) agentes serm o de alquilaciion) | |
CL2015001207A1 (es) | Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas, que comprende un análogo de oxintomodulina; y uso de la composición. | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
CL2011003350A1 (es) | Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
CL2007000876A1 (es) | Uso de un antagonista del factor de crecimiento endotelial vascular (vegf) en combinacion con un segundo agente que comprende un agente reductor de celula mieloide para tratar un tumor resistente en un sujeto; y metodo de diagnostico del tumor. | |
CL2008001076A1 (es) | Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2007002994A1 (es) | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. | |
ECSP10010559A (es) | Compuestos heterociclicos novedosos y usos de los mismos | |
CL2011000454A1 (es) | Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
CL2008001268A1 (es) | Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor. | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
CL2013000718A1 (es) | Un complejo de inclusion que comprende a) una ciclodextrina, b) fulvestrant y c) un portador; su metodo de preparacion; formulacion y forma de dosificacion que comprende al complejo; preparacion que comprende al complejo o a la formulación; y su uso en el tratamiento del cancer y lupus eritematoso sistemico, entre otras enfermedades. | |
CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. | |
CL2013001324A1 (es) | Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer. | |
CL2013001009A1 (es) | Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer. | |
CL2013000881A1 (es) | Combinaciones farmacéuticas que comprenden un componente (a) que corresponden a compuestos derivados de difenilurea omega-carboxiaril-sustituidos, (b) compuestos derivados de n-(2-arilamino)arilsulfonamida y (c) que son uno o más agentes farmaceuticos adicionales; y su uso en el tratamiento del cancer | |
CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. |